High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells

Journal of Neuroscience Research

Volumn 86, Issue 14, 2008, Pages 3212-3220

  Widmer, M ^a,b   Hanemann, C O ^a   Zajicek, John ^a  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b Merck Chemicals Ltd   (United Kingdom)

Author keywords

Cannabinoid receptors; CB1; Glioma; U373MG

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; PHOSPHOTRANSFERASE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL;

EID: 57049106235     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21757     Document Type: Article

References (51)

1. Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R, Alvarez L, Guzman M, Galve-Roperh I. 2007. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem 282:6854-6862.
2. Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN, Constantinescu CS, Calabrese V, Loesch A, Alexander SP, Clothier RH, Kendall DA, Bates TE. 2007. Cannabinoid receptor agonists are mitochondrial inhibitors: a uni.ed hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364:131-137.
3. Bifulco M, Laezza C, Pisanti S, Gazzerro P. 2006. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148:123-135.
4. Bouaboula M, Bourrie B, Rinaldi-Carmona M, Shire D, Le Fur G, Casellas P. 1995. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 270:13973-13980.
5. Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V, Malicet C, Villuendas R, Gironella M, Gonzalez-Feria L, Piris MA, Iovanna JL, Guzman M, Velasco G. 2006. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9:301-312.
6. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V. 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95:8375-8380.
7. De Vries TJ, Schoffelmeer AN. 2005. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26:420-426.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
9. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825.
10. Downer EJ, Fogarty MP, Campbell VA. 2003. Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol 140:547-557.
11. Downer EJ, Gowran A, Murphy AC, Campbell VA. 2007. The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by delta9-tetrahydrocannabinol in cultured cortical neurons. Eur J Pharmacol 564:57-65.
12. Efird JT, Friedman GD, Sidney S, Klatsky A, Habel LA, Udaltsova NV, Van den Eeden S, Nelson LM. 2004. The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors. J Neurooncol 68:57-69.
13. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD. 2005. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2:29.
14. Ellert-Miklaszewska A, Kaminska B, Konarska L. 2005. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17:25-37.
15. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. 2000. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6:313-319.
16. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. 2007. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 1128:61-69.
17. Gomez del Pulgar T, Velasco G, Guzman M. 2000. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347:369-373.
18. Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G. 2002. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277:36527-36533.
19. +-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol 70:1612-1620.
20. Guzman M, Sanchez C, Galve-Roperh I. 2002. Cannabinoids and cell fate. Pharmacol Ther 95:175-184.
21. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. 1998. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8:1195-1198.
22. Hall W, Christie M, Currow D. 2005. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6:35-42.
23. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. 2007. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83-92.
24. Held-Feindt J, Dorner L, Sahan G, Mehdorn HM, Mentlein R. 2006. Cannabinoid receptors in human astroglial tumors. J Neurochem 98:886-893.
25. Herrera B, Carracedo A, Diez-Zaera M, Gomez del Pulgar T, Guzman M, Velasco G. 2006. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 312:2121-2131.
26. Hetman M, Gozdz A. 2004. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur J Biochem 271:2050-2055.
27. Hohmann AG, Suplita RL, 2nd. 2006. Endocannabinoid mechanisms of pain modulation. AAPS J 8:E693-E708.
28. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
29. Jiang S, Fu Y, Williams J, Wood J, Pandarinathan L, Avraham S, Makriyannis A, Avraham S, Avraham HK. 2007. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS ONE 2:e641.
30. Katona S, Kaminski E, Sanders H, Zajicek J. 2005. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 140:580-585.
31. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
32. Liu J, Lin A. 2005. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15:36-42.
33. Matias I, Di Marzo V. 2006. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27-37.
34. McKallip RJ, Nagarkatti M, Nagarkatti PS. 2005. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174:3281-3289.
35. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR,et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
36. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza C. 2002. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22:9742-9753.
37. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM. 2005. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/ AKT signaling. Mol Cell Neurosci 28:189-194.
38. Molina-Holgado F, Rubio-Araiz A, Garcia-Ovejero D, Williams RJ, Moore JD, Arevalo-Martin A, Gomez-Torres O, Molina-Holgado E. 2007. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci 25:629-634.
39. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. 2006. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 103:696-701.
40. Pryce G, Baker D. 2007. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150:519-525.
41. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. 2003. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126:2191-2202.
42. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. 2005. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904-1913.
43. Richardson SJ, Widmer M, Zajicek J, Rule SA. 2007. Physiological doses of cannabinoids do not adversely affect MCL viability. Leukemia Lymphoma 48:1855-1857.
44. Rueda D, Galve-Roperh I, Haro A, Guzman M. 2000. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58:814-820.
45. Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M. 1998. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436:6-10.
46. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. 2006. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 281:39480-39491.
47. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
48. Wilson RI, Nicoll RA. 2002. Endocannabinoid signaling in the brain. Science 296:678-682.
49. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517-1526.
50. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. 2005. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76:1664-1669.
51. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. 1999. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96:5780-5785.